Veraxa Biotech Holding AG

VERAXA Biotech and Secarna Pharmaceuticals announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates for autoimmune and inflammatory diseases.

European Molecular Biology Laboratory reports beneficial ownership of 22,891,235 ordinary shares, representing 16.2% of Veraxa Biotech Holding AG, following a business combination.

David Lukas Deck has filed a Schedule 13D, revealing beneficial ownership of 25,502,836 ordinary shares, representing 18% of Veraxa Biotech Holding AG, acquired through a business combination.

Xlife Sciences AG has filed a Schedule 13D, reporting beneficial ownership of 23,029,967 ordinary shares, representing 16.3% of Veraxa Biotech Holding AG, acquired through a business combination.

Gilbert Edgar Schoeni has reported beneficial ownership of 22,539,749 ordinary shares, representing 15.9% of Veraxa Biotech Holding AG, following a business combination.

AQR Capital Management entities have filed a Schedule 13G, reporting a passive beneficial ownership of 0.46% in Veraxa Biotech Holding AG.